The partnership aims to deploy AI capabilities that automatically analyse X-ray and CT images to assist radiologists.

This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

This effort, undertaken by Bristol Myers Squibb and agency partner Real Chemistry, is part of the Champions in Care campaign.

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.

Bristol Myers Squibb’s oncology-focused campaign was developed in partnership with 2025 MM+M Agency 100 honoree Real ...

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

Harald Hampel is recognized as an influential leader in neuroscience, and will bring expertise in Alzheimer's disease to BMS.